GLP-1 therapies are reshaping obesity, diabetes, and even cardiovascular care Demand has outpaced global manufacturing capacity A grey market has emerged and regulators are now stepping in to contain it Patients want affordable, available treatment
What makes this one exciting is that its touted to be more affordable than Ozempic and others so far, meaning a lot more consumers may have access to weight loss drugs
Consequently the FDA issued a drug-specific black box warning for rosiglitazone concerning an increased risk of ischemic cardiovascular events (separate from the warning for increased risk of heart failure, which remains in effect)
[DOI] [Google Scholar] 245.Wang Q., Guo X., Yue Q., Zhu S., Guo L., Li G., Zhou Q., Xiang Y., Chen G., Yin W., et al
How GLP-1s May Help Men Reclaim Their Hormonal Health According to a 2023 narrative review in Medicina (Kaunas) , GLP-1 receptor agonists have shown promising benefits for obese men struggling with fertility
